Elevance Health, Inc.: stock overview

ELVNYSEHealthcare · Hospital & Medical Service Plans

Price

$429.69

November 13, 2026Market cap $94.8B

DCF calculator

What Ploutos Investor adds for Elevance Health

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Elevance Health had revenue of $202B over the last 12 months and net income of $5.1B, a net margin of 2.6%. Revenue grew by 10.3% a year on average over the last 5 years. At $429.69 the shares trade at a P/E of 18.5, against a median of 18.6 over the last 5 fiscal years. It holds more cash than debt, by $4.9B. It pays a dividend yielding 1.60%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$94.8B
221M shares
P/E
18.5
Today18.5
Median18.6
Revenue, 12 months
$202B
+10.3% a year over 5 years
Net margin
2.6%
2025: 2.8%, above 18% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+7.8% a year over 2 years

  • 202510-K
    Revenue$199B
  • 202410-K
    Revenue$177B
  • 202310-K
    Revenue$171B

Fiscal years in figures

ELV's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $83.9B
$94.8B
Enterprise value 
$89.9B
P/E 3-year median: 14.4
18.5
EV / EBIT 
16.6
EV / Revenue 
0.5
P/B 3-year median: 2.0
2.1
FCF yield 3-year median: 5.4%
6.9%
Earnings yield 3-year median: 7.0%
5.4%

Profitability

Gross margin 
89.0%
Operating margin 
2.7%
Net margin 3-year median: 3.4%
2.6%
ROIC 
5.9%
ROIC, 5-year average 
9.5%
ROE 
11.6%

Growth

Revenue, yearly change 
+12.5%
EPS, yearly change 
-1.8%
FCF, yearly change 
-30.3%
Revenue, average a year 
+10.3%
EPS, average a year 
+7.0%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$35.7B
Total debt 
$30.8B
Net cash 
$4.9B
Net debt / EBITDA 
-0.7x
Interest cover 
3.8x
Current ratio 
1.47

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 1.8%
1.60%
Buybacks 
2.75%
Total returned 
4.35%
Shares, yearly change 
-2.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 63).

Operating margin

3.6%

Above 52% of the 22 companies in its industry, and 46% of all.

Net margin

2.8%

Above 18% of the 109 companies in its industry, and 45% of all.

ROE

12.9%

Above 58% of the 108 companies in its industry, and 71% of all.

ROA

4.7%

Above 75% of the 110 companies in its industry, and 70% of all.

Revenue growth

12.5%

Above 68% of the 110 companies in its industry, and 68% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

Contracts with the US government

What the federal government committed in contracts to the company and its subsidiaries, by federal fiscal year (October to September).

$261M Fiscal year 2025

In federal fiscal year 2025 (October 2024 to September 2025) the US government committed $261M in contracts to the company and its subsidiaries. The year before it was $186M. That is about 0.1% of its revenue in the fiscal year to December 31, 2025 ($199B), though an amount committed is not revenue.

Fiscal year 2022Oct 2021 to Sep 2022

$345M

Fiscal year 2023Oct 2022 to Sep 2023

$435M

Fiscal year 2024Oct 2023 to Sep 2024

$186M

Fiscal year 2025Oct 2024 to Sep 2025

$261M

Fiscal year 2026Oct 2025 to Sep 2026

$282M

From USAspending.gov, the federal government's public spending records, as of November 1, 2026. An amount committed is not revenue of the same year: a contract running several years counts when it is signed, and the company is paid as it does the work. The company is matched through the parent company the government records it under, which adds up its subsidiaries. A subsidiary recorded under another parent can be missing.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Elevance Health, Inc.
CIK
1156039
Exchange
NYSE
Industry (SIC)
6324 · Hospital & Medical Service Plans
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
221M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Elevance Health's filings show?

These are Elevance Health's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ELV

Didn't find what you were looking for?

Ask us
What is ELV's market cap?

Elevance Health, Inc.'s market cap is $94.8B, at a price of $429.69 on November 13, 2026 and 221M shares.

What is ELV's P/E?

ELV's P/E is 18.5, on earnings per share of $23.52 over the last 12 months. The median over the last 5 fiscal years was 18.6.

How much revenue does ELV have?

Elevance Health had revenue of $202B over the last 12 months. Over the last 5 years it changed by +10.3% a year on average.

Does ELV pay a dividend?

Yes. Elevance Health paid $6.87 per share over the last 12 months, a yield of 1.60% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Elevance Health, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.